Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | HPGD | P15428 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | GLA | P06280 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | RUNX1 | Q01196 | 3/20 | 0.52 |
| ▸ | CBFB | Q13951 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2740062 | 0.82 | HPGD (0.48) | LMNAALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL15451212 | 0.70 | LMNA (0.49) | LMNAALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL24795860 | 0.70 | NPC1 (0.56) | LMNAALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL2740049 | 0.70 | MAPT (0.77) | LMNAMAPTKDM4EMAPK1HTT | |
| SCHEMBL2740045 | 0.69 | MAPT (0.75) | LMNAALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL10654161 | 0.69 | GAA (0.60) | LMNAALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL9231028 | 0.69 | PGR (0.83) | LMNAALDH1A1SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL2740071 | 0.69 | RORC (0.59) | LMNAALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL28470500 | 0.68 | ALDH1A1 (0.59) | LMNAALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL2740048 | 0.68 | MAPT (0.72) | LMNAALDH1A1HPGDMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143269-B2 | Inhibitors of store operated calcium release | CALCIMEDICA, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143269-B2 | Inhibitors of store operated calcium release | CALCIMEDICA, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | ORAI1, SARAF, RYR2 | LMNA 1170/4885ALDH1A1 4125/4885HPGD 1355/4885 |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | ORAI1, SARAF, RYR2 | LMNA 1170/4885ALDH1A1 4125/4885HPGD 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.